Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 11/4/15 → 5/3/18 |
Funding
- Genentech Inc: $30,493.00
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD L1 Antibody) Versus Observation as Adjuvant Therapy in Patients with PD L1-Positive, High-Risk, Muscle-Invasive Bladder Cancer After Cystectomy
- Wang, Peng (PI)
- Arnold, Susanne (CoI)
- James, Andrew (CoI)
- Myers, Adria (CoI)
- Strup, Stephen (CoI)